![]() |
市場調查報告書
商品編碼
1494821
到 2030 年植入式生醫材料的市場預測:按材料、應用、最終用戶和地區進行的全球分析Implantable Biomaterials Market Forecasts to 2030 - Global Analysis By Material (Natural Biomaterials, Ceramics and Composites), Application (Ophthalmology, Plastic Surgery and Other Applications), End User and By Geography |
根據 Stratistics MRC 的數據,2024 年全球植入式生醫材料市場規模將達到 1,121.6 億美元,預計到 2030 年將達到 2,553.9 億美元,在預測期內年複合成長率為 14.7%。
可植入生醫材料是設計用於植入體內用於醫療目的的材料,範圍從治療輸送系統到組織替代方案。旨在與生物系統相互作用,不會造成傷害或排斥。這些材料可以是合成的或天然的,它們的特性可以根據特定的應用進行客製化,例如生物相容性、機械強度和分解率。
據美國國家公共衛生機構疾病管制與預防中心稱,美國20 歲以上成年人中,每 20 人就有 1 人患有心血管疾病。
老年人口增加
由於多種因素,老年人口的增加是植入生醫材料市場的關鍵驅動力。首先,隨著年齡的成長,我們更有可能需要依賴生物材料的醫療干涉措施,例如關節關節重建、人工植牙和心血管植入。其次,老年人經常患有骨質疏鬆症、心血管疾病等與老齡化相關的疾病,需要使用生醫材料進行治療和支持。此外,醫療保健的進步導致預期壽命更長,進一步增加了對可植入生醫材料的需求。
基於生物材料的產品的局限性
儘管基於生物材料的產品具有非常先進的植入式醫療設備,但它們並非沒有限制。一個重要的限制是患者對這些材料的反應各不相同,這可能導致免疫反應和組織排斥。此外,隨著時間的推移,生物材料的劣化會損害設備的完整性和功能,需要頻繁更換或修改。開發和製造基於生物材料的植入的相關成本是另一個主要障礙,通常會導致患者支付高昂的費用。
植入生物材料的優惠報銷
植入式生醫材料的優惠報銷正在為植入式生醫材料市場創造重大機會。隨著醫療保健系統擴大承擔與這些材料相關的成本,患者正在轉向更先進、更耐用的解決方案。這正在推動需求和採用,推動市場成長。優惠的報銷也獎勵醫療保健提供者提供這些創新解決方案,進一步擴大市場。此外,該領域的研究和開發已經加速,並導致了更有效和通用的生物材料的引入。這些趨勢創造了市場擴張的環境,使患者和行業相關人員受益。
患者遭受嚴重災難或個人不幸
在植入式生醫材料市場中,材料排斥、植入失敗和感染疾病等因素可能會為患者帶來重大災難和個人不幸。當人體的免疫系統對植入材料產生負面反應時,就會發生材料排斥,導致併發症和潛在的健康風險。由於機械問題或與周圍組織的整合不當,可能會導致植入失敗,需要額外的手術或介入。移植期間或移植後的感染疾病對患者的健康狀況構成嚴重威脅,並可能導致全身性併發症。
COVID-19 的爆發對植入式生醫材料市場產生了重大影響。由於醫療資源的重新分配和安全問題,選擇性手術,包括需要植入生物材料的手術,已被推遲或取消。這減少了對此類材料的需求。此外,全球供應鏈和製造流程的中斷也影響了這些生物材料的可用性。然而,隨著醫療保健系統的適應和選擇性手術的恢復,市場預計將逐漸復甦。此外,對醫療基礎設施彈性和生醫材料技術創新的更多關注可能會推動市場未來的成長。
金屬和金屬合金部門預計將在預測期內成為最大的部門
由於多種因素,植入式生醫材料市場中的金屬和金屬合金領域正在經歷顯著成長。鈦及其合金等金屬因其優異的生物相容性、耐腐蝕和機械性能而成為關節重建、人工植牙等植入的理想材料。此外,冶金技術的進步促進了性能改進和客製化特性的新型合金的開發,進一步推動了該領域的成長。整形外科和牙科疾病的日益普及以及尋求植入的人口老化也促進了這一領域的擴張。
整形外科領域預計在預測期內年複合成長率最高
近年來,植入式生醫材料市場的整形外科領域經歷了顯著成長。這種成長是由於多種因素造成的。生物材料技術的進步促進了用於整形外科植入的耐用且生物相容性材料的開發,改善了患者的治療效果並減少了翻修手術的需要。此外,世界人口老化導致關節重建和脊椎手術等整形外科手術的增加,從而推動了對可植入生醫材料的需求。此外,患者和醫療保健提供者對這些植入益處的認知不斷提高,也推動了市場的擴張。
近年來,北美植入式生物材料市場經歷了顯著成長。這種快速成長歸因於多種因素,包括醫療技術的進步、醫療保健支出的增加和人口老化。此外,慢性病和肌肉骨骼疾病盛行率的上升也推動了全部區域對可植入生物材料的需求。此外,主要市場參與者的存在和積極的研發活動進一步刺激了市場擴張。監管支援和優惠報銷政策也在推動北美市場成長方面發揮著重要作用。
由於多種因素,亞太地區的植入式生醫材料市場正在顯著成長。醫療保健支出的增加、慢性病盛行率的增加以及人口老化正在推動對植入式醫療設備的需求。此外,生物材料技術和外科技術的進步正在支持市場擴張。在醫療基礎設施改善和醫療旅遊業激增的推動下,中國、醫療保健和日本等國家正在引領成長軌跡。此外,有利的政府措施和支持性法律規範正在鼓勵該地區的投資並進一步促進成長。
According to Stratistics MRC, the Global Implantable Biomaterials Market is accounted for $112.16 billion in 2024 and is expected to reach $255.39 billion by 2030 growing at a CAGR of 14.7% during the forecast period. Implantable biomaterials are substances designed to be placed inside the body for medical purposes, ranging from therapeutic delivery systems to tissue replacement. They are engineered to interact with biological systems without causing harm or rejection. These materials can be synthetic or natural, and their properties are tailored to specific applications, such as biocompatibility, mechanical strength, and degradation rate.
According to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, 1 in 20 adults age 20 and older have cardiovascular diseases.
The increase in the geriatric population
The rise in the geriatric population is a significant driver for the implantable biomaterials market due to several factors. Firstly, as people age, there's a greater likelihood of needing medical interventions such as joint replacements, dental implants, and cardiovascular implants, all of which rely on biomaterials. Secondly, older individuals often experience age-related conditions like osteoporosis or cardiovascular diseases, necessitating the use of biomaterials for treatment or support. Additionally, advancements in healthcare have led to increased life expectancy, further contributing to the demand for implantable biomaterials.
Limitations of biomaterial-based products
While biomaterial-based products have significantly advanced implantable medical devices, they are not without limitations. One key restraint lies in the variability of patient responses to these materials, leading to potential immune reactions or tissue rejection. Moreover, biomaterial degradation over time can compromise the device's integrity and functionality, necessitating frequent replacements or revisions. The cost associated with developing and manufacturing biomaterial-based implants is another significant barrier, often leading to higher prices for patients.
Favorable reimbursements for implantable biomaterials
Favorable reimbursements for implantable biomaterials present a significant opportunity in the implantable biomaterials market. With healthcare systems increasingly covering the costs associated with these materials, patients are more inclined towards advanced and durable solutions. This drives demand and adoption, boosting market growth. Favorable reimbursements also incentivize healthcare providers to offer these innovative solutions, further expanding the market. Moreover, it encourages research and development in the field, leading to the introduction of more effective and versatile biomaterials. This trend creates a conducive environment for market expansion, benefiting both patients and industry stakeholders.
Huge disasters or personal misfortunes for the patient
In the implantable biomaterials market, huge disasters or personal misfortunes for patients could arise from factors such as material rejection, implant failure, or infection. Material rejection occurs when the body's immune system reacts negatively to the implanted material, leading to complications and potential health risks. Implant failure can result from mechanical issues or improper integration with surrounding tissues, necessitating additional surgeries or interventions. Infections, either during or after implantation can pose serious threats to the patients' health condition and can lead to systemic complications.
The COVID-19 pandemic has significantly impacted the implantable biomaterials market. Elective surgeries, including those requiring implantable biomaterials, were postponed or cancelled due to healthcare resource reallocation and safety concerns. This led to a decline in demand for such materials. Additionally, disruptions in the global supply chain and manufacturing processes affected the availability of these biomaterials. However, as healthcare systems adapt and elective procedures resume, the market is expected to gradually recover. Furthermore, increased emphasis on healthcare infrastructure resilience and innovation in biomaterial technologies may drive future growth in the market.
The metals and metal alloys segment is expected to be the largest during the forecast period
The metals and metal alloys segment in the implantable biomaterials market has experienced significant growth due to several factors. Metals like titanium and its alloys are favored for their excellent biocompatibility, corrosion resistance, and mechanical properties, making them ideal for implants such as joint replacements and dental implants. Additionally, advancements in metallurgy have led to the development of new alloys with improved performance and tailored properties, further driving the segment's growth. The increasing prevalence of orthopedic and dental disorders, coupled with an aging population seeking implants, has also contributed to the expansion of this segment.
The Orthopaedics segment is expected to have the highest CAGR during the forecast period
The orthopaedics segment within the implantable biomaterials market has experienced significant growth in recent years. This growth can be attributed to several factors. Advancements in biomaterial technology have led to the development of more durable and biocompatible materials suitable for orthopaedic implants, enhancing patient outcomes and reducing the need for revision surgeries. Additionally, an aging population worldwide has contributed to the rise in orthopaedic procedures, such as joint replacements and spinal surgeries, driving demand for implantable biomaterials. Moreover, increasing awareness among patients and healthcare providers about the benefits of these implants has fueled market expansion.
In recent years, North America has experienced notable growth in the implantable biomaterials market. This surge can be attributed to several factors, including advancements in medical technology, increased healthcare expenditure, and a growing aging population. Additionally, the rising prevalence of chronic diseases and musculoskeletal disorders has fuelled the demand for implantable biomaterials across the region. Moreover, the presence of key market players and robust research and development activities has further stimulated market expansion. Regulatory support and favourable reimbursement policies have also played a significant role in fostering market growth in North America.
The Asia-Pacific region has witnessed significant growth in the implantable biomaterials market due to several factors. Rising healthcare expenditures, an increasing prevalence of chronic diseases, and a growing aging population are driving the demand for implantable medical devices. Moreover, advancements in biomaterial technology and surgical techniques have bolstered market expansion. Countries like China, India, and Japan are leading the growth trajectory, propelled by improving healthcare infrastructure and a surge in medical tourism. Additionally, favorable government initiatives and supportive regulatory frameworks have encouraged market players to invest in the region, further fueling growth.
Key players in the market
Some of the key players in Implantable Biomaterials market include 3M, Arthrex, BASF SE, Bayer AG, Berkeley Advanced Biomaterials, Biomet, Cam Bioceramics B.V., Carpenter Technology Corporation, Celanese Corporation, CeramTec, Collagen Solutions Plc, CoorsTek Inc., DuPont, Evonik Industries AG, Linden Lab, Medtronic, Royal DSM, Stryker Corporation and Zimmer Biomet Holdings.
In May 2024, Zimmer Biomet Holdings, Inc., a global medical technology leader, announced the successful completion of the world's first robotic-assisted shoulder replacement surgery using its ROSA Shoulder System. The surgery was performed at Mayo Clinic by John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minnesota, and a key contributor to the ROSA Shoulder development team.
In May 2024, Arecor and Medtronic say they partnered to create a new type of insulin that would allow for the use of new insulin pump designs. These new insulin pumps in mind would sit under the skin, rather than on the surface of the skin. The research collaboration aims to develop a novel, high-concentration, thermostable insulin for use by Medtronic in a next-generation pump. A new insulin of this kind could minimize the need for pump maintenance interventions and expand utility for physicians while saving costs.